Neutrophil/lymphocyte ratio has a prognostic value for patients with terminal cancer by unknown
RESEARCH Open Access
Neutrophil/lymphocyte ratio has a
prognostic value for patients with terminal
cancer
Yoichi Nakamura1,2*, Ryohei Watanabe2, Miwa Katagiri2, Yoshihisa Saida2, Natsuya Katada2, Manabu Watanabe2,
Yasushi Okamoto2, Koji Asai2, Toshiyuki Enomoto2, Takaharu Kiribayashi2 and Shinya Kusachi2
Abstract
Background: Determining prognosis in advanced cancer is of key importance. Various prognostic scores have
been developed. However, they are often very complex. In this study, we evaluated the feasibility of
neutrophil/lymphocyte ratio (NLR) as an index to estimate survival in terminal cancer patients.
Methods: NLR was calculated retrospectively based on blood tests performed at 3 months, 2 months, 4 weeks,
3 weeks, 2 weeks, 1 week, and within 3 days before death in 160 cancer patients (82 men, 78 women; age range,
33–99 years; mean age, 69.8 years).
Results: NLR increased significantly with time (P < 0.0001). Mean NLR was significantly higher in patients who
died within 4 weeks (29.82) than in those who lived more than 4 weeks (6.15). The NLR cutoff point was set at 9.
21 according to receiver operating characteristic curve analysis (area under the curve, 0.82; 95 % confidence
interval, 0.79–0.85). We inferred that life expectancy would be <4 weeks when NLR >9.21. The sensitivity,
specificity, positive predictive value, and negative predictive value were 65.6, 84.1, 90.6, and 51.1 %, respectively.
The positive and negative likelihood ratios were 4.125 and 0.409, respectively.
Conclusions: NLR appears to be a useful and simple parameter to predict the clinical outcomes of patients with
terminal cancer.
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Background
Determining prognosis in patients with advanced can-
cer is of key importance. Previous studies have shown
that physicians do not accurately estimate survival time
[1, 2]. A systematic review of the accuracy of clinical
predictions of survival in terminally ill cancer patients
has shown that physicians consistently overestimate
survival; however, their predictions are highly corre-
lated with actual survival [3].
Various prognostic scores have been developed. The
palliative prognostic score (PPS) [4] and the palliative
prognostic index (PPI) [5] are frequently used for
prognostic estimates in patients with terminal-stage
cancer, but these methods are not simple and often in-
clude subjective factors. These scores are widely used
by palliative care physicians to make the remaining
time that patients have left to live more meaningful.
However, oncologists regard them as complex predic-
tive formula. The inability to make accurate forecasts
about a patient’s prognosis is a reason why treatment
often runs counter to the patient’s expectations.
Therefore, we consider it important to have an index
that enables doctors to easily predict the prognosis of
cancer patients.
Neutrophil/lymphocyte ratio (NLR) is an immuno-
logical index commonly used in cancer therapy and
diagnosis [6–12]. In this study, we evaluated the feasibi-
lity of NLR as an index to estimate survival in terminal
cancer patients.
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Methods
This retrospective study included data from 160 con-
secutive patients who received palliative care and died in
the Toho University Ohashi Medical Center between
May 2011 and November 2013. The inclusion criteria
were (i) histologically or clinically confirmed malignant
tumor and (ii) death after hospitalization. We imple-
mented a comprehensive agreement method to obtain
consent from the patients regarding the study. The study
was approved by the ethical review board of Toho Uni-
versity Ohashi Medical Center.
Data on white blood cell (WBC) counts and neutrophil
and lymphocyte fractions (%) were extracted retrospect-
ively from electronic records of blood tests performed at
3 months, 2 months, 4 weeks, 3 weeks, 2 weeks, 1 week,
and within 3 days before death of the cancer patients.
NLR was calculated by dividing the absolute count of
band and segmented neutrophils by the number of lym-
phocytes in the complete blood count.
All statistical analyses were performed with EZR
(Saitama Medical Center, Jichi Medical University,
Saitama, Japan), the graphical user interface for R
(The R Foundation for Statistical Computing, Vienna,
Austria). More precisely, EZR is a modified version of
R commander designed to add statistical functions
frequently used in biostatistics [13]. Continuous vari-
ables were expressed as mean ± standard deviation.
Comparisons between time points were performed
using the Friedman rank sum test. Comparisons
between groups were performed using the t test. The
receiver operating characteristic (ROC) curve was
generated by plotting the sensitivity value against the
false-positive rate (1-specificity). We assessed the pre-
dictive value of life expectancy <4 weeks by calculat-
ing the area under the curve (AUC) and estimated the
optimal cutoff value based on maximum sensitivity
and specificity. Differences were considered statisti-
cally significant if the null hypothesis could be
rejected with >95 % confidence (P < 0.05).
Results
The average age of the patients (82 men, 78 women) was
69.8 years (age range, 33–99 years). Patient characteris-
tics and primary tumor sites are shown in Table 1. The
feasibility of using NLR was evaluated from 735 data
points.
The median NLR values were 3.83 at 3 months before
death, 5.38 at 2 months, 8.53 at 4 weeks, 10.22 at
3 weeks, 11.48 at 2 weeks, 21.16 at 1 week, and 37.40
within 3 days (Table 2). NLR values increased signifi-
cantly with time (P < 0.0001) (Fig. 1).
The mean NLR value of patients who lived more than
4 weeks was 6.15 ± 5.86, while that of those who died
within 4 weeks was 29.82 ± 44.19; a significant difference
was observed between the two groups (P < 0.00000001)
(Table 3).
In ROC analysis, the area under the curve was 0.82
(95 % confidence interval (CI), 0.79–0.85) (Fig. 2). Using
a cutoff point of NLR of 9.21, life expectancy was
assumed to be <4 weeks yielded a sensitivity of 65.6 %,
(95 % CI, 61.4–69.7 %), specificity of 84.1 % (95 % CI,
78.6–88.7 %), positive predictive value (PPV) of 90.6 %
(95 % CI, 87.2–93.4 %), negative predictive value (NPV)
of 51.1 % (95 % CI, 45.8–56.4 %), positive likelihood
ratio of 4.125 (95 % CI, 3.025–5.626), and negative likeli-
hood ratio of 0.409 (95 % CI, 0.358–0.467).
Discussion
Prognostic scoring tools are applied to predict the life
expectancy of terminal cancer patients. In daily clinical
Table 1 Patient characteristics (n = 160)
Age, mean (range) 69.8 (33–99) years
Sex, male/female 82:78
Site of primary tumor Lung 33 CUP 7
Colon/rectum 32 Esophagus 5
Stomach 25 Cervix 5
Breast 13 Uterine body 4
Pancreas 11 Ovary 3
Biliary tract 7 Ureter 2
Bladder 7 Other 6
CUP cancer of unknown primary
Table 2 NLR values at various times before death
Time before death Numbers of patients Neutrophils × 109/L,
mean ± standard deviation
Lymphocytes × 109/L,
mean ± standard deviation
NLR, mean ± standard deviation
(median)
3 months 109 4.84 ± 3.99 1.07 ± 0.54 5.64 ± 6.30 (3.83)
2 months 111 5.62 ± 3.45 0.99 ± 0.52 6.65 ± 5.36 (5.38)
4 weeks 112 7.93 ± 5.02 0.87 ± 0.49 12.28 ± 11.25 (8.53)
3 weeks 99 7.90 ± 4.23 0.78 ± 0.50 13.91 ± 13.83 (10.22)
2 weeks 110 9.10 ± 5.71 0.84 ± 1.03 25.15 ± 36.93 (11.48)
1 week 100 11.53 ± 7.48 0.55 ± 0.41 44.28 ± 56.62 (21.16)
3 days 96 13.50 ± 11.25 0.52 ± 0.71 57.74 ± 61.41 (37.40)
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practice, tools such as PPS and PPI are used by pallia-
tive care physicians [4, 5]. Here, we suggest the use of
NLR as a simple tool to estimate survival in terminal
cancer patients.
PPS grades the clinical prediction of survival, anorexia,
Karnofsky’s performance status, dyspnea, WBC count,
and lymphocyte count. A lower grade means a lower life
expectancy (within 30 days). One disadvantage of this
tool is that it considers the clinical prediction of survival,
which is a subjective parameter [4].
PPI includes various parameters such as the existence
of edema, dyspnea at rest, delirium, PPS grade, and the
amount of oral intake. However, some of these parame-
ters are also subjective. In patients with PPI grade 6 or
higher, life expectancy is <3 weeks with a sensitivity of
83 %, specificity of 85 %, PPV of 80 %, and NPV of
87 %. In patients with PPI grade 4 or higher, the sensi-
tivity is 79 %, specificity is 77 %, PPV is 83 %, and NPV
is 71 % [5].
Besides their subjectivity, PPS and PPI are complex.
Therefore, they are not commonly used by specialists
other than palliative care physicians (e.g., oncologists
and general practitioners). Accurately predicting life
expectancy would enable clinicians to provide more ap-
propriate end-of-life care for terminally ill patients, who
would like to think how they wish to spend their
remaining time. However, unreliable predictions could
lead clinicians to administer unnecessary body-rending
chemotherapy and mislead the patients’ preferences.
These problems are more likely to occur in cases in
which palliative care physicians are not involved.
According to Glare et al. [3], physicians tend to in-
terpret the prognosis more optimistically. Therefore,
easy-to-use, objective prognostic tools are needed.
The development of such tools could be useful for
oncologists and healthcare providers in daily clinical
and home-based care.
In our earlier studies, we discussed about the prognos-
tic nutritional index (Onodera’s PNI), which depends
only on objective data such as serum albumin level and
peripheral lymphocyte count [14]. This was originally
used in digestive surgery to evaluate the patients’ pre-
operative nutritional condition, and anastomosis of di-
gestive tract was considered contraindicated in cases of
grades of 40 and under [15]. It was also considered to be
a prognosis index in stage IV cancer of the digestive
tract. It was used as a vague predictive formula that es-
timated the possibility of death within 60 days when
the patient was graded 35 and under. PNI showed
lower value as time proceeded, and therefore, it was
considered a feasible factor to estimate the prognosis of
patients with terminal cancer.
In this study, we evaluated NLR as a simple prognostic
index of survival in terminal cancer patients. This
method requires minimal blood test items, and thus, it
would be a least invasive approach to the patient. The
prognosis prediction by NLR is believed to have mode-
rate accuracy, with 0.81 area under the curve according
to ROC analysis and a 4.125 positive likelihood ratio.
It has been reported that critically ill cancer patients
in the intensive care unit exhibit high NLR values [16].
Other studies have shown that pre-treatment NLR could
serve as a feasible prognosis factor in cases of non-
small-cell lung cancer [6], ureteral cancer [7], esopha-
geal squamous cell cancer [8], biliary tract cancer [9],
unresectable gastric cancer [10], liver cancer [11], and
pancreatic cancer [12].
NLR is an inflammation marker. There is a strong
relationship between inflammation and cancer. But
the mechanism of neutrophilia in cancer patients is
not fully understood, and it is believed to be the result
of a combination of factors. One obvious cause of
neutrophilia is paraneoplastic production of myeloid
growth factors, such as granulocyte colony-stimulating
factor, by cancer cells themselves. Other possible fac-
tors that cause neutrophilia are coexistent infection
and cancer-related inflammation [17]. Lymphocytes
play a critical role in tumor defense, inducing cyto-
toxic cell death through the immune response. Lym-




































Fig. 1 The time course of the NLR value. NLR values increased
significantly with time
Table 3 Mean NLR of the patients who lived more than or up to 4 weeks
More than 4 weeks Up to 4 weeks P value
NLR, mean ± standard deviation 6.15 ± 5.86 29.82 ± 44.19 P < 0.00000001
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advanced cancer, reflecting cancer-related immuno-
suppression [18]. Therefore, neutrophilia and lympho-
penia worsen with the progression of cancer. NLR
increases with time in patient with terminal cancer.
This study also has some limitations. First, it was per-
formed on a relatively small population, but our major
aim in this pilot study was merely to assess the feasibility
of using the NLR as an index to estimate survival in
patients with terminal cancer, using our consecutive
patients. Second, this study had a retrospective, single-
center design, and a potential bias in the selection of pa-
tients. Finally, this study analyzed patients with various
cancer, and it is not known whether the significance of
the NLR for predicting life expectancy is consistent irre-
spective of the type of cancer. To improve the prediction
of prognosis of terminal cancer, it may be necessary to
combine other indices together with the NLR. Thus, lar-
ger, prospective studies will need to be performed to
confirm these preliminary results.
Conclusions
In the present study, the NLR has emerged as a feasible
factor for prognosis prediction in terminal-stage cancer.
NLR is easy to determine based on blood test results and
could be applied by cancer clinicians as well as healthcare
providers who do not specialize in palliative medicine.
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